ITEVIIIR Antibody

What are the fundamental characteristics of therapeutic antibodies in research settings?

Understanding these binding characteristics is essential for antibody development, as failures in late-stage development become increasingly costly. Many research groups have invested heavily in elucidating factors causing these failures and developing screening methods to identify and eliminate antibodies with problematic risk profiles . These screening efforts are critical since antibodies with molecular liabilities can result in unacceptably poor pharmacokinetics, reduced potency, limited bioavailability, or increased immunogenicity .

How do researchers differentiate between polyreactivity and polyspecificity in antibody research?

Polyreactivity and polyspecificity represent two distinct phenomena with significant implications for therapeutic antibody development:

Polyreactivity refers to a fundamental "sticky" characteristic where antibodies bind non-specifically to various structures with low affinity and specificity . This property is often associated with early B-cell repertoires, which maximize protective potential by generating antibodies that can bind to a large variety of potential structures. The early repertoire predominantly generates large, polyvalent, highly avid antibodies in the IgM format to compensate for low initial binding affinity .

Polyspecificity involves discrete off-target reactivity of meaningful affinity to structurally and/or functionally disparate targets . This phenomenon is more complex to uncover but can significantly impact clinical performance. Several case studies have demonstrated that polyspecificity can cause accelerated clearance and unpredictable toxicities in therapeutic applications .

Understanding these differences is crucial because both phenomena can lead to antibody development failures through different mechanisms. Researchers must implement appropriate screening strategies to identify and eliminate antibodies exhibiting problematic levels of either polyreactivity or polyspecificity early in development .

What role do T-cells play in the immune response to protein-based therapeutics?

T-cells serve a critical function in the immune response to protein-based therapeutics by helping activate B cells to produce antibodies, including those that may block protein therapeutics . This interaction becomes particularly problematic when the natural protein made by the body is defective in some way .

In such cases, T-cells may respond to a normal, artificial protein therapeutic as if it were foreign, since it differs from the defective natural protein the body produces . This T-cell response mismatch is observed in conditions like hemophilia A, where patients lack sufficient quantities of functional FVIII protein, which is critical for blood clotting .

While infusion of FVIII therapeutic protein has been one of the most successful examples of chronic disease management, the development of anti-drug antibodies against the infused FVIII significantly impedes treatment efficacy . Treatment of patients who develop an immune response becomes more complex, less effective, and exceedingly expensive .

Research has shown that individual variations in the tendency to develop anti-drug antibodies may also be genetically based, reflected in the clinical observation that persons with hemophilia A of Black African descent are twice as likely as patients of European Caucasian descent to produce antibodies against factor VIII proteins given as replacement therapy .

What screening methods can identify antibodies with polyreactivity issues early in development?

Several high-throughput methods have been developed to identify and eliminate polyreactive antibodies from the discovery pipeline at an early, relatively inexpensive stage . These assays have been established using panels of antibodies for which in vivo clearance data are known, enabling predictions for new antibodies:

• Baculovirus binding assay: Established by Hötzel et al., this was the first surrogate assay shown to predict in vivo pharmacokinetics .

• ELISA-based formats measuring:

  • Nonspecific binding to cell membrane preparations

  • Charge-mediated binding to negatively charged molecules including FcRn, heparin, DNA, and insulin

• Plate-based assays measuring binding to heparin and HEK293 cell membranes, which directly correlate with in vivo observations .

These assays are particularly effective at identifying antibodies with polyreactivity caused by "charge imbalance" . Implementation of such screening methods is crucial because strong polyreactivity profiles have been linked to high-profile late-stage clinical development failures, such as bococizumab, which suffered from short PK, poor biodistribution, and high immunogenicity in humans .

The Jain et al. study demonstrated the value of this type of screening in predicting successful progression of antibodies through late-stage development, showing that a strong polyreactivity profile is one of several risk factors that could potentially increase the likelihood of failure in clinical development .

How are AI technologies being applied to advance therapeutic antibody discovery?

Artificial intelligence technologies are revolutionizing therapeutic antibody discovery by addressing traditional bottlenecks in the process . Vanderbilt University Medical Center has recently been awarded up to $30 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop AI-based approaches for antibody discovery through:

• Building a massive antibody-antigen atlas

• Developing AI-based algorithms to engineer antigen-specific antibodies

• Applying the AI technology to identify and develop potential therapeutic antibodies

These efforts aim to address the significant limitations of traditional antibody discovery methods, which suffer from inefficiency, high costs and fail rates, logistical hurdles, long turnaround times, and limited scalability . According to project principal investigator Ivelin Georgiev, PhD, the proposed approach will "address all of these big bottlenecks with the traditional antibody discovery process and make it a more democratized process—where you can figure out what your antigen target is and have a good chance of generating a monoclonal antibody therapeutic against that target in a very effective and efficient way" .

Over recent decades, monoclonal antibodies have gained importance as therapeutics across various disease settings, but current methods are just scratching the surface of their potential. The AI-driven approach represents a transformative high-risk, high-reward research direction that could significantly expand the impact of antibody therapeutics .

What molecular factors contribute to accelerated clearance of therapeutic antibodies?

Multiple molecular characteristics have been identified that contribute to accelerated clearance of therapeutic antibodies:

Understanding these molecular factors is essential for designing therapeutic antibodies with favorable pharmacokinetic profiles and reducing the risk of development failures.

How can researchers predict antibody pharmacokinetics (PK) during early development phases?

Predicting antibody pharmacokinetics during early development involves several complementary approaches:

• FcRn affinity column with pH gradient elution: This technique mimics FcRn-IgG dissociation at physiological pH and can predict in vivo PK . Studies have demonstrated a direct correlation between FcRn elution time and in vivo PK, with extended retention time on the FcRn column being predictive of accelerated clearance in vivo .

• Surrogate binding assays: Multiple assays have been established that correlate with in vivo clearance:

  • Baculovirus binding assay established by Hötzel et al.

  • ELISA-based formats measuring nonspecific binding to cell membrane preparations

  • Assays measuring charge-mediated binding to negatively charged molecules (FcRn, heparin, DNA, insulin)

• Structural and biophysical analysis: Analyzing the pI values, local charge distribution, and hydrophobic patches on the antibody surface can provide insights into potential clearance issues . It's important to note that antibodies with high pI values do not necessarily have poor PK if they have balanced local charge distribution .

• In vitro cell-based systems: Plate-based assays measuring binding to heparin and HEK293 cell membranes have shown direct correlation with in vivo observations and can serve as predictive tools .

• Self-association and aggregation assessment: Monitoring indicators like increased retention on SEC columns and nonspecific tissue binding in cross-reactivity studies can help identify antibodies prone to aggregation, which can affect PK .

By implementing these predictive approaches early in development, researchers can identify and eliminate antibodies with potentially unfavorable PK profiles before investing in costly late-stage development, significantly improving the efficiency of the therapeutic antibody development process.

What strategies can minimize immunogenicity in therapeutic antibody design?

Several sophisticated strategies can be employed to minimize immunogenicity in therapeutic antibody design:

• Genetically engineered protein designs: One approach involves designing genetically engineered proteins that don't trigger immune reactions . While designing proteins that are safe for all immune systems is challenging due to human diversity, it might be feasible to create versions adapted to specific populations where clear immunological differences exist (e.g., between those of European Caucasian and Black African descent) .

• Personalized immunogenicity prediction: Developing a gene-based approach to identifying individuals whose immune system is likely to react to specific versions of genetically engineered therapeutic proteins allows for personalized treatment strategies . The long-term goal is to enable treatment with protein versions less likely to cause immune responses in specific patients .

• T-cell epitope prediction and engineering: Methods to predict the interaction of T-cell epitopes with specific MHC Class II antigens can guide protein engineering efforts . For proteins like FVIII, predicting these interactions is crucial since immunogenicity against therapeutic versions significantly impedes successful treatment .

• Aptamer-based shape monitoring: Using aptamer-based approaches to determine if therapeutic proteins have shapes that might trigger antibody production provides another screening tool . If an aptamer loses its ability to bind to a protein (e.g., FVIII), it may indicate that part of the protein has changed shape, increasing the likelihood of triggering an immune reaction .

• Adaptation to population differences: In cases where there are significant differences between specific populations, adapting the designs of therapeutic proteins to each group ensures that one population doesn't receive a disproportionate share of the benefits while another bears a disproportionate share of the risks .

These strategies address the clinical observation that certain patient populations, such as persons with hemophilia A of Black African descent, are twice as likely as patients of European Caucasian descent to produce antibodies against therapeutic proteins like factor VIII .

How can charge distribution be optimized to improve antibody performance?

Optimizing charge distribution is crucial for improving antibody performance, particularly in terms of pharmacokinetics and tissue specificity:

What methods can identify off-target binding that may cause toxicity?

Identifying off-target binding that may cause toxicity requires a multi-faceted approach:

• Immunoblotting and peptide ELISAs: These techniques can detect cross-reactivity due to conformational homologies between proteins . In one study, these methods revealed cross-reactivity between an anti-β-amyloid antibody and the microtubule-binding protein tau due to conformational similarities .

• Complex proteomics analysis: When traditional immunoprecipitation methods fail to identify off-target interactions (possibly due to lower affinity binding), more sophisticated proteomics approaches become necessary . In one case study, after a series of statistical and empirical analyses of age-grouped proteomics data, integrin αIIbB3 was identified as the culprit off-target antigen causing platelet activation and thrombocytopenia .

• Species-specific testing: Off-target toxicity may be species-specific, necessitating testing with primary cells from multiple species . For example, one antibody caused platelet activation only with cells from macaque species, not from other non-human primates or human cells ex vivo .

• Mechanistic investigation: Understanding the mechanism of off-target binding provides insights into potential toxicities . One study revealed that platelet activation required both interaction with a platelet target via the Fab fragment and engagement of FcγRIIa via the Fc to induce sufficient cross-linking .

• In vivo toxicity monitoring: Careful monitoring for toxicities in animal studies can provide early indications of off-target binding issues . The development of ABT-736 (an anti-β-amyloid antibody) was discontinued due to severe toxicities observed in cynomolgus monkey studies, including infusion reactions, ataxia, emesis, tremors, decreased body temperature, and thrombocytopenia .

These methods are crucial for identifying potential safety issues before advancing therapeutic antibodies to clinical development, where off-target toxicities can lead to serious adverse events and development failure.

How can researchers address antibody self-association and aggregation issues?

Addressing antibody self-association and aggregation issues involves several strategic approaches:

• Surface hydrophobicity analysis: Identifying surface-exposed hydrophobic amino acids that drive nonspecific interaction is critical . In one case study, three such residues introduced during engineering led to increased viscosity and aggregation in an anti-nerve growth factor antibody, despite successful affinity optimization to 69 pM Kᴅ .

• Chromatographic behavior monitoring: Significantly increased retention on a size exclusion chromatography (SEC) column can indicate nonspecific interaction with the column matrix, revealing potential aggregation issues . This serves as an early warning sign during antibody characterization.

• Binding assay correlation: The baculovirus binding ELISA can help identify antibodies with nonspecific interaction tendencies that may lead to aggregation . This assay has been validated as predictive of in vivo behavior and can be implemented during early screening.

• Tissue cross-reactivity assessment: Broad tissue cross-reactivity studies can reveal antibodies prone to nonspecific binding, which often correlates with aggregation propensity . Nonspecific tissue binding observed in these studies served as a red flag for one antibody that later showed accelerated clearance in vivo .

• Structure-guided engineering: Understanding the structural basis of self-association allows for rational engineering approaches to address these issues while maintaining target binding affinity and specificity. This might involve replacing problematic residues with ones less likely to promote aggregation.

• In vivo PK correlation: Accelerated PK in vivo often correlates with aggregation issues and can serve as an indicator of potential problems . Early PK studies in relevant animal models can identify antibodies with unfavorable characteristics before significant resources are invested in their development.

By implementing these strategies early in development, researchers can identify and address self-association and aggregation issues before they lead to failures in later stages due to poor bioavailability, unexpected pharmacokinetics, or increased immunogenicity.

What approaches can detect and resolve species-specific off-target reactivity?

Detecting and resolving species-specific off-target reactivity requires sophisticated approaches:

• Multi-species comparative testing: Evaluating antibody binding and functional effects across cells and tissues from multiple species can reveal species-specific reactivity patterns . In one case study, platelet activation was observed only with primary cells from macaque species and not from other non-human primates or human cells ex vivo .

• Mechanistic investigations: Understanding the molecular mechanism behind species-specific reactivity is crucial for addressing it effectively . One study revealed that platelet activation required both Fab-mediated interaction with a platelet target and Fc-mediated engagement of FcγRIIa to induce sufficient cross-linking .

• Advanced proteomics analysis: When traditional identification methods fail to identify the off-target protein, complex proteomics approaches become necessary . Age-grouped proteomics analysis followed by statistical and empirical analyses successfully identified integrin αIIbB3 as the off-target antigen responsible for observed toxicity in one case study .

• Sequence and structural homology analysis: Comparing protein sequences and structures across species can help identify the molecular basis for species-specific reactivity. Differences in homologous proteins between species may explain why certain antibodies interact differently across species.

• Alternative lead selection: When species-specific off-target reactivity is identified, selecting alternative lead antibodies from the same discovery campaign that do not exhibit the problematic reactivity often provides the most practical solution . In one study, other antibodies derived during the same lead discovery campaign did not cause the same adverse effects observed with the problematic antibody .

• Targeted engineering: Once the molecular basis of species-specific off-target reactivity is understood, targeted engineering approaches can potentially eliminate the unwanted interaction while preserving desired target binding.

These approaches help researchers navigate the complex challenge of species-specific off-target reactivity, which can confound preclinical development and lead to unexpected toxicities that may or may not translate to humans.

How can researchers correlate in vitro assay results with in vivo antibody performance?

Correlating in vitro assay results with in vivo antibody performance requires systematic approaches:

By implementing these correlation approaches, researchers can better predict which antibodies are likely to succeed in vivo, potentially reducing the high failure rates and costs associated with therapeutic antibody development.

What parameters predict successful progression of antibodies through late-stage development?

Several key parameters have been identified that predict successful progression of antibodies through late-stage development:

By evaluating these parameters early in development through appropriate screening assays and predictive models, researchers can better select antibody candidates likely to succeed in late-stage development and clinical use, potentially reducing the high failure rates and costs associated with therapeutic antibody development.

How can researchers reconcile contradictory data on antibody performance across different studies?

Reconciling contradictory data on antibody performance requires comprehensive analysis considering multiple factors:

By taking a comprehensive, mechanism-based approach to data analysis, researchers can better understand apparent contradictions and develop more robust predictive models for antibody performance, ultimately improving the efficiency and success rate of therapeutic antibody development.